AbbVie Inc (ABBV)
167.80
-1.74
(-1.03%)
USD |
NYSE |
Apr 24, 16:00
167.32
-0.48
(-0.29%)
Pre-Market: 06:40
AbbVie Revenue (TTM): 54.32B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.32B |
| September 30, 2023 | 55.14B |
| June 30, 2023 | 56.02B |
| March 31, 2023 | 56.74B |
| December 31, 2022 | 58.05B |
| September 30, 2022 | 57.82B |
| June 30, 2022 | 57.35B |
| March 31, 2022 | 56.72B |
| December 31, 2021 | 56.20B |
| September 30, 2021 | 55.17B |
| June 30, 2021 | 53.73B |
| March 31, 2021 | 50.20B |
| December 31, 2020 | 45.80B |
| September 30, 2020 | 40.65B |
| June 30, 2020 | 36.23B |
| March 31, 2020 | 34.06B |
| December 31, 2019 | 33.27B |
| September 30, 2019 | 32.87B |
| June 30, 2019 | 32.62B |
| March 31, 2019 | 32.65B |
| December 31, 2018 | 32.75B |
| September 30, 2018 | 32.19B |
| June 30, 2018 | 30.95B |
| March 31, 2018 | 29.61B |
| December 31, 2017 | 28.22B |
| Date | Value |
|---|---|
| September 30, 2017 | 27.27B |
| June 30, 2017 | 26.71B |
| March 31, 2017 | 26.22B |
| December 31, 2016 | 25.64B |
| September 30, 2016 | 25.24B |
| June 30, 2016 | 24.75B |
| March 31, 2016 | 23.78B |
| December 31, 2015 | 22.86B |
| September 30, 2015 | 21.91B |
| June 30, 2015 | 20.99B |
| March 31, 2015 | 20.44B |
| December 31, 2014 | 19.96B |
| September 30, 2014 | 19.62B |
| June 30, 2014 | 19.26B |
| March 31, 2014 | 19.02B |
| December 31, 2013 | 18.79B |
| September 30, 2013 | 18.88B |
| June 30, 2013 | 18.74B |
| March 31, 2013 | 18.54B |
| December 31, 2012 | 18.38B |
| September 30, 2012 | 18.04B |
| June 30, 2012 | 17.94B |
| March 31, 2012 | 17.72B |
| December 31, 2011 | 17.44B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
32.62B
Minimum
Jun 2019
58.05B
Maximum
Dec 2022
48.58B
Average
54.32B
Median
Dec 2023
Revenue (TTM) Benchmarks
| Amgen Inc | 28.19B |
| Immunogen Inc (DELISTED) | 287.61M |
| Johnson & Johnson | 89.66B |
| Eli Lilly and Co | 34.12B |
| Merck & Co Inc | 60.11B |